Pfizer Ventures
Profile, fund size and portfolio
Pfizer Ventures is the corporate venture arm of Pfizer Inc. (pharmaceuticals). It was founded in 2004 and is based in New York, United States. It invests from Seed to Late stage in oncology, inflammation and Immunology, cardiovascular.
Every figure links to its source
Snapshot
Data behind this graphic
| Item | Value |
|---|---|
| Stage range | Seed to Late stage |
| Sectors | Oncology, Inflammation and Immunology, Cardiovascular, Metabolic/Obesity, Vaccines |
| Geography | North America, Europe, Asia, Middle East and Africa (Portfolio companies by region, from the firm's portfolio page) |
| Offices | New York, United States |
Sources: S1 Pfizer Ventures page (pfizer.com); S2 Pfizer Ventures portfolio page (active and former tabs).
Data behind this graphic
| Item | Companies | Share |
|---|---|---|
| Exited | 50 | 52.1% |
| Active | 46 | 47.9% |
Status as the firm tags it
Sources: S2 Pfizer Ventures portfolio page (active and former tabs).
Data behind this graphic
| Measure | Value | Unit | Kind | Source |
|---|---|---|---|---|
| Headline size | Not disclosed by the firm. | |||
| Companies backed | 121 | companies | Stated by the firm | S2 |
| Exits | 50 | exits | Stated by the firm | S2 |
| Companies on the firm's portfolio page | 121 | companies | Counted from the firm's own list | S2 |
Sources: S2 Pfizer Ventures portfolio page (active and former tabs).
Where it invests and who leads it
Geography
- Headquarters
- New York, United States
- Offices
- New York, United States
Portfolio companies by regionS1S2
Portfolio companies by region, from the firm's portfolio page
LeadersS6S7S8S9S1
- Michael C. Diem, MDVice President, WWBD / Senior Managing PartnerLinkedInFirm page
- Rana Al-Hallaq, PhDVice President, WWBD / Partner (Head of Operations)LinkedInFirm page
- Irena Melnikova, PhDExecutive Director, WWBD / PartnerLinkedInFirm page
- Christopher O'Donnell, PhDVice President, WWBD / PartnerLinkedInFirm page
- Marie-Claire Peakman, MRCPharm, PhDExecutive Director, WWBD / PartnerFind on LinkedInFirm page
Key facts
| Fact | Value | Status | Source |
|---|---|---|---|
| Parent company | Pfizer Inc. (NYSE: PFE) | Single source | S1 |
| Parent industry | Pharmaceuticals | Single source | S1 |
| Founded | 2004 | Single source | S3 |
| Headquarters | New York, United States | Single source | S1 |
| Status | Active | Single source | S1 |
| Capital source | Parent company only | Single source | S1 |
| Companies backed | 121 | Single source | S2 |
| Exits | 50 total | Single source | S2 |
| People on the team page | 12 | Single source | S1 |
| Stages | Seed, Series A, Series B, Series C+, Late stage | Single source | S1 |
Portfolio
The firm's portfolio page lists 121 companies: 46 active, 50 exited.S2
| Tag | Companies | Share |
|---|---|---|
| Active | 46 | 38% |
| Exited | 50 | 41.3% |
Every company on the Pfizer Ventures list
121 companies, as listed on the firm's own website: 50 exited, 46 active, 25 listed.S2 Read the firm's list.
Exited 50
- 4D Molecular Therapeutics
- Ablexis
- Aquinox Pharmaceuticals
- Avid Radiopharmaceuticals
- BioAtla
- BioNTech
- Bolt Biotherapeutics
- Capstan Therapeutics
- Clovis Oncology
- Cortexyme
- CytomX Therapeutics
- DVS Sciences
- eFFECTOR Therapeutics
- Eiger Biopharmaceuticals
- Evolution Benefits
- Flexion Therapeutics
- G-CON Manufacturing
- Genomic Health
- Handylab
- HD Biosciences
- Imara
- ImCheck Therapeutics
- Interius BioTherapeutics
- Jnana Therapeutics
- Kymera Therapeutics
- Lodo Therapeutics
- M2S
- Mersana Therapeutics
- Merus
- miRNA Therapeutics
- Mitokinin
- Morphic Therapeutic
- NeuMoDx Molecular
- Neuronetics
- NextCure
- NovoCure
- Petra Pharma
- Pyxis Oncology
- RaNA Therapeutics
- Rhythm Pharmaceuticals
- SpringWorks Therapeutics
- superDimension
- SupplyScape
- TetraLogic Pharmaceuticals
- Therachon
- Vaccine Company
- VectivBio
- Vtesse
- Yumanity Therapeutics
- Ziarco Pharma
Active 46
- Anaveon
- Aquinnah Pharmaceuticals
- Arrakis Therapeutics
- Artios Pharma
- Autifony Therapeutics
- Autobahn Therapeutics
- BioGraph 55
- Cartography Biosciences
- Crossbow Therapeutics
- Curve Therapeutics
- DEM Biopharma
- Enara Bio
- Enlaza Therapeutics
- Enodia Therapeutics
- EvolveImmune Therapeutics
- Flare Therapeutics Inc.
- FoRx Therapeutics
- Greywolf Therapeutics
- Immunocodex
- ImmunOs Therapeutics
- Incendia Therapeutics
- Kestrel Therapeutics
- Levicept Limited
- Mediar Therapeutics
- MindImmune Therapeutics
- Mission Therapeutics
- Montis Biosciences
- Mozart Therapeutics
- National Resilience
- Nimbus Therapeutics
- Normunity
- Nucleome Therapeutics
- Oblenio Bio
- OTR Therapeutics
- Palleon Pharma
- Prescriber Point
- ReCode Therapeutics
- RefleXion Medical
- Saama Technologies
- Storm Therapeutics
- Strata Oncology
- TRex Bio
- Triana Biomedicines
- TRIMTECH Therapeutics
- TwoStep Therapeutics
- Vibrant Therapeutics
Listed 25
- Accelerator Corporation
- Adapsyn Bioscience
- AMRA Medical AB
- Anjarium Biosciences
- Arkuda Therapeutics
- Aureon Laboratories
- Aviir
- Blade Therapeutics
- BlueLight Therapeutics
- Complexa, Inc.,
- Cydan & Cydan II, Inc.,
- DIR Technologies
- Entelos
- Epic Sciences
- Ixchelsis Limited
- Magnolia Neurosciences
- Metabomed
- NexImmune
- Nodality
- Quartet Medicine
- Second Genome
- Simcha Therapeutics
- System1 Biosciences
- Triplet Therapeutics
- VitaDAO
For founders
| Item | What the firm says | Source |
|---|---|---|
| Stages | Seed, Series A, Series B, Series C+, Late stage | S1 |
| Check size | USD 5M to USD 20M | S1 |
| Leads rounds | Yes. "We can lead or join investor syndicates" | S1 |
| Contact form | www.pfizer.com/about/partners/submit-your-opportunities | S5 |
Notable outcomes
IPOs and acquisitions of portfolio companies. Price shown only where published.
Recent rounds
Fund vehicles
| Vehicle | Size | Year | Note | Source |
|---|---|---|---|---|
| China-based venture vehicle with a local VC group | Not published | 2025 | Terms not published | S3 |
Investments by year
History
Where sources disagree
Official pages
Read the firm's own pages for current information.
Sources
- S1Pfizer Ventures page (pfizer.com)Firm
- S2Pfizer Ventures portfolio page (active and former tabs)Firm
- S3Pfizer Ventures 2025 in Review brochure (PDF)Firm
- S4Pfizer Ventures 2024 in Review brochure (PDF)Firm
- S5Pfizer: Submit your opportunitiesFirm
- S6Pfizer: Michael Diem bio pageFirm
- S7Pfizer: Rana Al-Hallaq bio pageFirm
- S8Pfizer: Irena Melnikova bio pageFirm
- S9Pfizer: Christopher O'Donnell bio pageFirm
- S10Global Venturing: Barbara Dalton retirement (29 Dec 2023)Press
- S12SEC EDGAR: Pfizer Inc (CIK 78003)Filing
- S13Wayback: Pfizer Ventures portfolio capture 18 Jun 2026Firm
- S14FundingWatcher corporate venture capital listThird-party report
Disclaimer and corrections
Not affiliated. This page is not affiliated with, endorsed by or sponsored by Pfizer Ventures or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.
Spotted a mistake? Report a correction.